" /> Lutadenovec Autogene - CISMeF





Preferred Label : Lutadenovec Autogene;

NCIt synonyms : Adenoviral TSNA Priming Vaccine GRT-C901; Priming Cancer Vaccine GRT-C901; Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901;

NCIt definition : A personalized cancer vaccine comprised of a chimpanzee adenovirus vector (ChAdV) encoding twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patient's tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of lutadenovec autogene, the adenovirus infects cells and expresses the TSNAs. This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis. Adenoviral-TSNA vaccine GRT-C901 is followed by monthly boosting with a self-amplifying mRNA (SAM) boosting vaccine that encodes the same 20 target TSNAs. The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001.;

UNII : AJ42U9BVW4;

CAS number : 2805319-15-5;

Molecule name : GRT-C901; GRT C901;

NCI Metathesaurus CUI : CL935908;

Détails


Position du mot-clé dans l'(les) arborescence(s) : arborescence

Vous pouvez consulter :


Nous contacter.
31/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.